Edit

AskBio

https://askbio.com/

Last activity: 15.01.2026

Active

Categories: BiotechClinicalTrialsGeneTherapyHealthcareR&D

AskBio is a leading, clinical-stage gene therapy company dedicated to developing AAV gene therapies for genetic and complex disorders. Learn more about our gene therapy technology and current clinical trials.

Mentions

Location: United States

Total raised: $235M

Twitter

Facebook

Youtube

Investors 2

Date	Name	Website
-	Vida Ventu...	vidaventur...
02.09.2021	TPG	tpg.com

Funding Rounds 1

Date	Series	Amount	Investors
15.04.2019	-	$235M	Vida Ventu...

Mentions in press and media 20

Date	Title	Description
15.01.2026	Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease	SHANGHAI, Jan. 15, 2026 /PRNewswire/ -- AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accep...
10.01.2022	AskBio Names Philip Dana Chief Human Resources Officer	RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2022 /PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company and a wholly owned and independently operated subsidiary of ...
28.06.2021	AskBio Receives FDA Fast Track Designation for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
25.05.2021	AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA
06.05.2021	AskBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy's 24th Annual Meeting
17.02.2021	Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
27.10.2020	ColumbusVP sale de AskBio tras el acuerdo de compra de Bayer por hasta $4.000 millones	27/10/2020 COLUMBUS VENTURE PARTNERS SALE DE ASKBIO TRAS EL ACUERDO DE COMPRA DE BAYER POR HASTA $4.000 MILLONES. La firma de capital riesgo (venture capital) Columbus Venture Partners, cofundado por el empresario valenciano Damià Tormo y...
26.10.2020	Bayer Acquires Asklepios BioPharmaceutical	Bayer AG acquired Asklepios BioPharmaceutical, Inc., a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. Under the terms of the agreem...
26.10.2020	Bayer paying up to $4B for gene therapy pioneer AskBio	Founded in 2001 and based in Research Triangle Park, North Carolina, AskBio brings a nearly 20-year track record of innovation in adeno-associated virus gene therapy under the direction of co-founder Richard Jude Samulski. The company’s pip...
27.04.2020	Asklepios BioPharmaceutical Acquires BrainVectis	Asklepios BioPharmaceutical, Inc., a Research Triangle Park, NC-based clinical-stage adeno-associated virus (AAV) gene therapy company, acquired BrainVectis, a Paris, France-based gene therapy company and French National Institute for Healt...
16.08.2019	DIGIT Tech News Roundup: 16th of August 2019	Cyan Forensics leads fight against child exploitation with US Partnership Napier University spin-out Cyan Forensics has secured a major US partnership to help tackle child exploitation. @CyanForensics @MissingKids https://t.co/0wzO6Qp7Vo — ...
16.08.2019	AskBio Buys Synpromics	AskBio, a Research Triangle Park, N.C.-based clinical stage and gene therapy platform company, acquired Synpromics, an Edinburgh, United Kingdom-based developer of gene control synthetic promoter technology, bioinformatics and intelligent d...
15.04.2019	Chapel Hill-Based AskBio Raises $225 Million From TPG Capital and Vida Ventures	-
11.04.2019	Asklepios BioPharmaceutical Receives $235M in Funding	Asklepios BioPharmaceutical, a developer and manufacturer of Adeno-Associated Virus (AAV) gene therapy therapeutics for underserved patient populations with rare and generally untreatable genetic disorders, raised $235m in funding. TPG Capi...
11.04.2019	Daily funding roundup - April 11th, 2019	Shedul.com landed $20M; Affectiva secured $26M; Mavenlink raised $48M; HistoSonics received $54M Fauna Bio: Fauna Bio is a biotechnology company leveraging the science of hibernation to improve healthcare for humans. Fauna Bio has raised $4...
11.04.2019	AskBio Lands $235M Financing From TPG And Vida Ventures	RESEARCH TRIANGLE PARK, N.C.& FORT WORTH, Texas & SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Asklepios BioPharmaceutical, Inc (AskBio), a developer and manufacturer of Adeno-Associated Virus (AAV) gene therapy therapeutics for und...
11.04.2019	AskBio’s $235 million financing provides clues to the direction of gene therapy investment	The North Carolina gene therapy company Asklepios BioPharmaceutical (named after the Greek god of medicine, and known as “AskBio” for short) announced Thursday that it had raised $235 milllion. That, even by the standards of the foamy, frot...
17.10.2017	Columbus Venture Partners and AskBio Launch Gene Therapy Joint Venture	CHAPEL HILL, N.C.–(BUSINESS WIRE)–Asklepios BioPharmaceutical, Inc. (AskBio) announced today the formation of Viralgen, a gene therapy joint venture with Columbus Venture Partners. The Viralgen Vector Core will use AskBio’s technology for t...
10.09.2007	Life sciences briefing: Monday, Sept. 10, 2007	Featured companies: BioVascular, Carefx, ClinResearch, Healthcare Management Directions, NanoCor, OxyPlus, Revitus, Spotlight Surgical, United BioSource UPDATED: See below. Healthcare IT provider Carefx pulls in $17.9M — Carefx, a Scottsdal...
-	Bayer paying up to $4B for gene therapy pioneer AskBio	Deepening its commitment to gene therapy, Bayer is paying $2 billion upfront to purchase a pioneer in the field, Asklepios BioPharmaceutical, known as AskBio. The deal, expected to close in the fourth quarter, includes the potential for ano...

AskBio

Investors 2

Funding Rounds 1

Mentions in press and media 20

Reviews 0